Tesla (NASDAQ: TSLA) and Biogen (NASDAQ: BIIB) have similar market caps of roughly $40 billion and both companies have seen their stocks fall by roughly 25% this year. While Biogen stock has declined after it ended phase-3 trials of its Alzheimer's drug Aducanumab in March, Tesla's stock has been...
Tesla (NASDAQ: TSLA) and Biogen (NASDAQ: BIIB) have similar market caps of roughly $40 billion and both companies have seen their stocks fall by roughly 25% this year. While Biogen stock has declined after it ended phase-3 trials of its Alzheimer's drug Aducanumab in March, Tesla's stock has been...
Share this Article
Recommended